Marshall Wace, LLP Catalyst Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 140,823 shares of CPRX stock, worth $2.96 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140,823Holding current value
$2.96 Million% of portfolio
0.0%Shares
16 transactions
Others Institutions Holding CPRX
# of Institutions
386Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$393 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$115 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$68.3 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$66.9 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.16B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...